Patent · US Active

Substituted pyridones as inhibitors of poly(ADP-ribose) polymerase (PARP)

US8173682B2 · kind B2 · utility

0Cited by

4References

6Claims

0Family size

Assignee

Aventis Pharmaceuticals Inc. · US

Inventors

Philip M. Weintraub · Cincinnati, US
Paul Robert Eastwood · Romford, GB
Shujaath Mehdi · Manville, US
David Stefany · Fryeburg, US
Kwon Yon Musick · Raritan, US
Neil Moorcroft · Bloomsbury, US
Sungtaek Lim · Flemington, US
John Ziqi Jiang · Fryeburg, US
Hartmut Rutten · Idstein, DE
Stefan Peukert · Frankfurt am Main, DE
Uwe Schwahn · Frankfurt am Main, DE

Key dates

Filing date	Sep 26, 2006
Grant date	May 8, 2012
Priority date	—
Expiry date	Oct 29, 2030

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D417/14
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to a series of 2,3,5-substituted pyridone derivatives of formula I:wherein R, R1, R2, R3 and R4 are as defined herein. This invention also relates to methods of making these compounds. The compounds of this invention are inhibitors of poly(adenosine 5′-diphosphate ribose) polymerase (PARP) and are therefore useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of diseases, including diseases associated with the central nervous system and cardiovascular disorders.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.